Fresh Recalls

FDANot Yet Classified · Drug · FDA event 99421; recall number pending · Recalled August 5, 2026

Dabigatran Etexilate Capsules recall — Ascend Laboratories, LLC

Agency report date: August 5, 2026.

1. Compare your item

This notice names a product; your particular item is not yet verified. Compare every applicable model, serial, lot, production-date or model-year boundary below.

Product named
Dabigatran Etexilate Capsules
Company / brand
Ascend Laboratories
Lot / serial / date codes
Lot: 25141586, Exp. April 30, 2027.
Distribution
Within the U.S Market.
Agency product description and boundaries

Dabigatran Etexilate Capsules, 75 mg, 30-count (3x10) blister pack, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268, NDC 0904-7253-04.

Still to verify: match the label on your item with the full official notice, including any exclusions, tables and photos. Some identifiers appear only on the agency website and are absent from this data feed. A missing field does not mean all versions are affected.

If your lot or date falls outside a stated range, this notice has not established that your item is affected. This is not a finding about other recalls or product safety.

2. Agency hazard and consumer action

FDA reports: Failed impurity/degradation specification:12M Long-term Stability conditions (25 ¿2 ¿C/60 ¿5%RH), an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities

No consumer remedy instructions are supplied in this record. Check the official notice and listed company contact for the agency’s current instructions.

Affected product: Dabigatran Etexilate Capsules

3. Open the official notice or contact

Official recall ID
Not yet assigned by the FDA — identified by FDA event ID 99421
Brand
Ascend Laboratories
Classification
Not Yet Classified
Units affected
936 cartons x 12 x 3 x 10 (in blister pack)
Recall status
Ongoing
Initiated
Voluntary: Firm initiated

Affected products

Companies & origin

Recalling firm location
Bedminster, NJ, United States
Firm address
135 Us Highway 202 206 Ste 15, N/A, 07921-2608

Identifying details (verbatim from the notice)

Product codes / lots
Lot: 25141586, Exp. April 30, 2027.
Distribution
Within the U.S Market.
Firm notified the public via
Letter
FDA event ID
99421
Recall initiated
July 16, 2026
FDA report date
August 5, 2026
Verify with the official sources:

Found something wrong or missing? Report a data error.

Source: U.S. Food & Drug Administration. Agency excerpts come from the public data feed and may omit tables or later changes; the linked government source is authoritative. Source last checked September 7, 2026 at 6:00 AM UTC. Record retrieved August 18, 2026 at 12:00 AM UTC.

Report a data error on this page